Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment The Phase 1 APOLLO study is investigating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results